Absci and Merck collaborate to develop new enzymes
As part of the collaboration, the company will use its Deep Learning-Enabled Drug Creation and Bionic Protein non-standard amino acid technologies to create enzymes to meet Merck’s biomanufacturing
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
An investigational antibody-drug conjugate (ADC), Teliso-V targets c-Met receptor tyrosine kinase that is overexpressed in tumours that include NSCLC. It is indicated to treat nonsquamous NSCLC patients with
AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.